Introduction
The knee joint capsule contains three tissues that function in harmony to provide biomechanical support: ligaments, menisci, and cartilage. The menisci are semilunar wedgeshaped fibrocartilaginous tissues, which absorb shocks between the articular cartilage of the tibia and femur (Figure 1) . The primary biomechanical function of meniscus comprises of providing shock absorption and overall mechanical stability in the knee. [1] The biochemical composition of human meniscus is reported to vary between 72 and 78% water, 13 and 23% collagen (mostly type-I collagen), 0.4 and 0.5% glycosaminoglycans (GAGs), and about 0.12% deoxyribonucleic acid (DNA), [2] depending on the location. [3, 4] The meniscus has a unique discusses the state-of-the-art research in cellular therapies and novel cell sources for these therapies. Section 3 reports the research on acellular biomaterial implants, which are being developed or in clinical trials. Finally, the combined approach of cell-based therapies and biomaterials is discussed in Section 4.2.
Clinical Treatments for Meniscal Injury
The meniscus is the most commonly injured structure in the human knee. While meniscus repair is an option in young patients with traumatic injuries, degenerative tears in older patients require meniscectomy-removal of the torn portion of the meniscus. [14] Even in younger patients, meniscus deficiency can result from failed meniscus repairs or meniscectomy, the natural history of a meniscectomized knee suggests that osteoarthritis ensues. In 1948, Fairbank described the characteristic changes in the knee joint following meniscectomy that now bear his name and are understood to be osteoarthritis. [15] To date, the clinical interventions to meniscus injuries in young patients have revolved around meniscus repair techniques. Suturing of the meniscus has been facilitated with advancements in knee arthroscopy, allowing for numerous suture configurations and the introduction of more biological repair strategies, such as use of platelet rich plasma (PRP) or blood clot augmentation. [16] Until recently, there have been few options for the partial replacement of meniscus. One recent product, the collagen meniscus implant (CMI, also known as Menaflex) has seen promising results in Europe and has become available in the United States. [17] The challenge of partial replacement is finding a scaffold that is robust enough to allow strong suture repair yet compressible enough to avoid articular cartilage damage with weight bearing. In addition, the central portion of the meniscus has a poor blood supply, further hampering the success of graft incorporation and healing.
In cases of complete or subtotal meniscus deficiency, the only current option is the replacement of the total meniscus, using meniscus allograft transplantation (MAT), especially in the young and active patient population. [10] This complex procedure uses a once frozen meniscus from an organ donor. The graft is size matched based upon the tibial plateau anatomy and is sewn into position with or without the fixation of bone plugs at the roots. The graft sizing has been studied extensively, but despite this knowledge, intraoperative size issues often occur. [18] Over time, these grafts have not been seen to decrease in size, but more often to become extruded from the knee joint, which may have more to do with the host mechanical environment and osteophyte formation between meniscus excision and replacement. [19] Graft storage, processing, and sterilization are other concerns that tend to get overlooked, which affect the mechanical properties of the graft and the metabolic activity of the surviving cells after thawing. [13, 20] A retrospective review reported an overall failure rate of 29% of MAT (4-14 year post op). [21] Another analysis of literature indicated that MAT seemed to have higher reoperation and failure rates than the available acellular meniscal scaffolds (Actifit polyurethane meniscal scaffold and CMI collagen meniscal implant). [22] A gap exists where meniscus surgeons have few options for meniscus replacement in patients with meniscus deficiency. This need warrants the continuous work on viable tissue engineering constructs in this domain. 
Cell Sources for Meniscus Regeneration and Repair
The limited vascularity of the meniscus contributes to its poor healing response. In particular, the inner meniscus referred to as the ww region is devoid of blood vessels. Much like articular cartilage, the ww region of the meniscus is dependent on synovial fluid for nourishment. Given that inner peripheral meniscal tears present a significant clinical challenge, it is clear that neither the synovial fluid nor the neighboring tissues alone can stimulate an adequate repair response in the ww region. It is with this in mind that growth factors and platelet-rich plasma have been used in past decades to try and augment peripheral healing. In the case of PRP specifically, although some studies have reported improvements in meniscal healing compared to PRP untreated controls, [23] there are also studies that have reported minimal to no healing response. [24, 25] Comparatively, cell-based tissue regeneration has emerged as a promising avenue toward improving meniscus repair. An emerging strategy uses cells that can adhere to the meniscus and/or migrate to the area of injury in order to facilitate an improved repair response. [26] [27] [28] As one can imagine, this relies heavily on the reparative capabilities of the cells themselves and the efficiency of their method of delivery. As such, a considerable amount of ongoing effort by researchers focuses on finding an optimal cell source and delivery method to use in this strategy. Investigators have thus far explored the use of mesenchymal stem cells (MSCs) from several sources including bone marrow, adipose tissue, synovium, and meniscus itself (see below sections in detail for each cell source). Furthermore, the use of non-load-bearing cartilage derived MSCs for meniscus repair is promising and further investigation of their reparative potential is being explored in Dr. Jayasuriya's laboratory. In this section, we will review the cell sources that have been explored to demonstrate potential for cell-based meniscus repair ( Table 1) .
Stem Cells
Although they are in short supply compared to fully differentiated cells, stem cells exhibit several key features that make them desirable for tissue repair. For instance, MSCs lack human leukocyte antigen (HLA) class II expression rendering them effectively invisible to alloreactive lymphocytes [30] thus Adipose-derived stem cells (ASCs) Fat [28, 57] Meniscus-derived mesenchymal stem cells (MMSCs) Meniscus [59, 60] Cartilage progenitor cells (CPCs) Cartilage [64] Myoblasts Muscle [70] Multipotent vascular endothelial cells Endothelium [72] granting them reduced immunogenicity in comparison to mature cells. These cells also secrete immunoregulatory factors such as indoleamine 2,3-dioxygenase [31] and prostaglandin E2 (PGE2), which suppress the activation of immune cells. [32] Stem cells are also self-renewing and highly proliferative upon activation. [33] There are several sources of stem and progenitor cells that have demonstrated promise for use in meniscus repair.
Mesenchymal Stem Cells
The most studied type of stem cell in the field of musculoskeletal research is the mesenchymal stem cell. MSCs are reported to exist in a wide variety of musculoskeletal tissues including bone marrow, [34] cartilage, [35] synovium, [36] tendon, [37] ligament, [38] intrapatellar fat pad, [39] and even meniscus itself. [40] Many of these tissues have been utilized as stem cell sources for cell-based meniscus repair strategies in animal models. Currently, bone marrow and synovium are the most commonly explored sources of MSCs. Bone Marrow: Stromal cells from the bone marrow (BM-MSCs) were first discovered by Friedenstein et al. in 1968 . [34] While relatively easy to collect, they only make up 0.0017-0.0201% of bone marrow cells. [41] BM-MSCs are CD34−, CD44+, CD45−, CD54−, CD90+, CD105+, and CD166+ cells that exhibit the ability to differentiate along the chondrogenic, osteogenic, and adipogenic lineage. [42] These cells can be extracted autologously through minimally invasive bone marrow aspiration procedure. [43] BMMSCs have been utilized in many preclinical meniscal repair studies. They have been used in the repair of meniscal tears [27, 44] and meniscal defects, [25] including partial meniscus transections. [45, 46] A reported disadvantage associated with the use of BM-MSCs for the purpose of tissue repair is their propensity for hypertrophic differentiation. Indeed, the occurrence of cellular hypertrophy of BM-MSCs has been brought to light in cartilage defect repair [47] and meniscus coculture studies. [48] Currently, there is a need to address this limitation-either through finding conditions that can prevent hypertrophy in BM-MSCs themselves or through the discovery of alternative cell sources that are more resistant to cellular hypertrophy altogether. With respect to the former, coculturing BM-MSCs with meniscal cells from the outer meniscus has led to a reduction of hypertrophic differentiation of BM-MSCs in vitro. [49] Coculturing a larger proportion of meniscus cells, relative to BM-MSCs, in a 3:1 ratio in the presence of TGF-beta resulted in a significant reduction of hypertrophic markers collagen X (COL10A1) and matrix metalloproteinase-13 (MMP-13), compared to BM-MSCs alone. [50] Culturing BM-MSCs embedded in powderized meniscal ECM components have also been reported to reduce hypertrophy. [51] With this being said, cellular hypertrophy remains the primary limitation that fuels criticism against utilizing BM-MSCs as a cell source for cartilage and meniscus repair.
Synovium: Synovium-derived mesenchymal stem cells (SMSCs) are a promising cell source for meniscus repair. These cells are reported to be chondrogenic and to form more colonies than BM-MSCs under monolayer culture conditions. [36] SMSCs have a similar gene expression profile to meniscus cells, as determined by cluster analysis. [52] In vitro culture expansion of synovial cells results in increasing percentage of SMSCs that express CD271, [53] a marker reported to be indicative of MSCs with enhanced differentiation potential. [54] Additionally, obtaining synovial tissue in order to isolate synovial cells does not compromise the articular surface and is therefore an attractive feature of their consideration for meniscus repair strategies. Meniscus repair in large animals has been investigated with moderate success using SMSCs. [55] While these studies brilliantly demonstrate that type II collagen is elevated in the SMSC treated menisci, relative to untreated controls, it would be beneficial for future studies to also measure Collagen X and other markers of cellular hypertrophy as well as degradative MMP levels.
Adipose Tissue: Adipose-derived stem cells (ASCs) from the infrapatellar fat pad of the knee are considered an alternative source of stem cells that are in consideration for emerging cellbased cartilage and meniscus repair strategies. Although these cells are isolated from fat tissue, they demonstrate the ability to undergo chondrogenic differentiation producing proteoglycans and type II collagen. Unlike bone marrow stromal cells, but similar to SMSCs, isolation of autologous ASCs typically require initial surgery for tissue extraction. Studies have demonstrated the limited chondrogenic potential of ASCs in comparison to BM-MSCs [56] thereby dampening enthusiasm in their consideration for cartilaginous tissue repair. However, CD90 and CD49e double positive ASCs were reported in one study to improve healing of surgically created 5 mm meniscal lesions in the inner avascular region in a rabbit model. The authors demonstrate that the presence of a healing response is very much dependent on the size of the lesion and how long after the creation of the lesion the meniscus is treated with ASCs. [57] In another study, ASCs were isolated from subcutaneous neck fat in rats, labeled with iron oxide and localized to the site of a partial meniscal transection using magnets in order to evaluate the healing response of these cells when they are directed to the site of injury. [28] The authors demonstrated a notable increase in neomeniscal size in ASC treated groups at the 12-week time point.
Meniscus: The use of meniscus-derived MSCs (MMSCs) is one of the latest developments in cell-based meniscus repair/ regeneration. Like most stem cells, MMSCs are reported to be highly adherent to tissue culture plastic. Isolation of MMSCs involves allowing these cells from either the vascularized redred outer region or avascular white-white region to migrate out of meniscal tissue onto plastic (Figure 2A) . Migrated individual cells that exhibit high colony forming efficiency (CFE) and also undergo multilineage differentiation have been used for meniscus repair in ex vivo and live animal models. [58] [59] [60] A significant challenge in considering autologous MMSCs for cell-based tissue repair is that it seems inherently counterintuitive to extract cells from menisci in order to repair the same meniscal tissue. Instead, utilization of allogeneic MMSCs is a practical approach that has been demonstrated to promote meniscus healing in multiple animal models. [59, 60] Similar to MSCs from other tissue sources, MHC class II expression is lacking in MMSCs thereby minimizing the chance of allogeneic cell rejection. [60] MMSCs have been shown to be chemotactically attracted to SDF-1, the production of which is elevated in the meniscus up to three weeks following injury. [59] The involvement of the SDF-1/CXCR4 pathway in mediating MMSC migration to meniscal injury sites is being explored.
Cartilage: Similar to the aforementioned bone marrow, adipose tissue, synovium, and meniscus, cartilage too harbors tissue-specific mesenchymal stem cells. [35, 61] These cells are often referred to as cartilage-derived chondrogenic progenitor cells (CPCs). CPCs from cartilage can be effectively and inexpensively separated from mature chondrocytes and enriched through differential adhesion to fibronectin ( Figure 2E ) as first demonstrated by Williams et al. [61] These cells are reported to be highly proliferative and capable of trilineage differentiation along chondrogenic, osteogenic, and adipogenic lineages. [62] Seol et al. demonstrated that CPCs are capable of mobilizing to sites of cartilage injury and/or trauma. [63] The authors reported that this migratory response to distress could be attenuated by inhibiting the receptor for advanced glycation end products (RAGE). CPCs from cartilage are fibrochondrocyte-like in appearance and they are recognized for their high colony forming efficiency and chondrogenic potential. It is for these reasons that they should not only be considered for cell-based cartilage defect repair, but also meniscus repair. Cartilage CPCs can adhere and integrate into the avascular ww zone of the meniscus (Figure 3b,c) . Furthermore, we show that these cells retain the ability to produce proteoglycans thereby remaining chondrogenic upon integration (Figure 3d ). In comparison to BM-MSCs, CPCs from healthy cartilage tissue are resistant terminal differentiation and hypertrophy. [64] However, as is the case with synovium-derived mesenchymal stem cells, a challenge to using cartilage-derived CPCs in regenerative medicine is their bioavailability. CPCs are reported to make up less than 1% of all cells in articular cartilage; [65] although one study has reported 1.47 ± 0.16% fibronectin adherent progenitor cell colonies from normal healthy human cartilage. [66] Given their low natural abundance, their high colony forming efficiency becomes essential for expansion and their use in cell-based repair strategies. Indeed much like the established method of autologous chondrocyte implantation [67] in which healthy chondrocytes are relocated from nonload bearing regions of cartilage to a tissue defect, it should be possible to expand CPCs isolated from nonload bearing cartilage in order to use these cells autologously to repair meniscus tissue. Intriguingly, osteoarthritic (OA) cartilage harbors an even greater number of progenitor cells than found in normal healthy cartilage. [66, 68] Fellows et al. [66] recently demonstrated that there are OA CPCs that exhibit characteristics of early senescence as well as those that seem to retain normal proliferative capacity, giving the implication that the latter may be utilized as a source of cell-based regenerative therapy. However, it must be taken into consideration that some OA CPCs also exhibit a propensity for premature hypertrophy and mineralization in culture. [69] Hence, it is with the upmost care that risk factors be weighed before using these cells for therapeutic purposes.
Myoblasts
Few studies have explored the use of muscle-derived progenitors such as myosatellite cells and myoblasts for meniscus repair. Recently, Gu et al. [70] demonstrated that myoblasts subjected to chondrogenic differentiation in vitro can then be seeded into a polyglycolic acid (PLGA) mesh scaffold and used to repair a partially transected meniscus. The authors were able to achieve integration in all 12 canines implanted with the myoblast-seeded scaffold, 9 (75%) of which contained fibrocartilage tissue. Only 17% of animals implanted with cell-less composite scaffolds showed the presence of fibrocartilage tissue. In a later study, Zhu et al. utilized myoblasts genetically transfected to constitutively express cartilage-derived morphogenetic protein-2 (hCDMP-2). [71] 
Multipotent Vascular Endothelial Cells
As is the case with fat cells and muscle cells, isolating endothelial cells is convenient due to their abundance. With this consideration, multipotent progenitor cells from endothelial tissue have become an attractive cell source to investigate for cell-based tissue repair. A recent study demonstrated the reparative capacity of CD34+, CD146+ multipotent vascular endothelial cells from human fetal menisci using an athymic rat model. [72] The authors reported that CD34+/CD146+ cells achieved more complete healing of a surgically created radial tear on the inner avascular region that ran two-third of the way toward the back periphery, compared to cells that were double negative for these markers.
Mature Cells
Some nonstem/progenitor cells have also been investigated for use in meniscus repair strategies including cells from cartilage, meniscus, synovium, and adipose tissue. [73, 74] Meniscus repair was found to be least effective when using mature adipose cells, while chondrocytes and fibrochondrocytes have been reported to hold promise in multiple studies. [73, 74] However, it is worth noting that many of these studies would greatly benefit from exploring the quality of the resulting repair/regenerated tissue. For example, since a major limitation of utilizing BMMSCs for cell-based meniscus repair is the occurrence of tissue hypertrophy, any alternative cell source (including mature cells) should also be tested for this outcome. 
Meniscal Fibrochondrocytes
Fibrochondrocytes from meniscus have been investigated as a cell source for meniscus repair and transplantation. Meniscal fibrochondrocytes are most commonly utilized as a cell source to seed meniscal scaffolds. [75] [76] [77] One study demonstrated that these cells help to form neo-menisci when grown on a biodegradable scaffold and transplanted into rabbits. [78] However, there are not many studies that investigate the regenerative effects of these cells outside of a meniscal scaffold. In a 2015 study by Yuan et al., it was demonstrated that human umbilical vein endothelial cells (HUVECs) can regulate the regional migration of bovine fibrochondrocytes in an ex vivo explant model of a cylindrical meniscal defect at full thickness. [79] Scaffolds were not used in this study. The authors reported that endothelial factor endothelin-1 increased fibrochondrocyte cell proliferation and migration to the interface of the defect thereby enhancing reintegration of cylindrically cut tissue core with the rest of the meniscus. Although it is true that there is a greater quantity of fibrochondrocytes in the meniscus than there are MMSCs, isolation of these fibrochondrocytes requires sacrificing healthy meniscal tissue. This drastically hinders the consideration of autologous fibrochondrocytes as a viable cell source for tissue engineering and regenerative medicine. This is the reason that a prioritized emphasis should be placed on optimizing the usage of allogeneic donor-derived fibrochondrocytes for cell-based tissue repair instead.
Chondrocytes
Chondrocytes from articular cartilage, costal cartilage, and auricular cartilage have been explored for use in meniscal repair. [73] Out of these three sources, autologous and allogeneic chondrocytes from articular cartilage have been the most frequently used in conjunction with scaffolds to try and repair meniscal lesions and defects. [80, 81] A recent study reported that chondrocytes can be enhanced by treatment with PRP to improve cell attachment and meniscal tissue repair in a polylactic-co-glycolic acid scaffold. [82] As is the case with fibrochondrocytes, not many studies have utilized chondrocytes in the absence of some sort of scaffold or mesh. An earlier study reported the successful use of autologous articular chondrocytes in conjunction with allogeneic meniscal slices to repair a porcine model of a longitudinal meniscal tear in the avascular zone. [83] In the case of articular chondrocytes, the utilization of allogeneic cells is ultimately preferable to sacrificing healthy load bearing articular cartilage in order to extract cells for this purpose. However, if this is challenging, a viable alternative is to obtain autologous articular chondrocytes from nonload bearing regions of the joint.
Finding the "Ideal" Cell Population for Meniscus Repair
While it is undeniable that advances in cell-based tissue repair are being made yearly, certain obstacles firmly remain. In the case of load-bearing tissue like meniscus and cartilage, a successful healing response must be capable of overcoming compressive and shearing motion that is commonplace in the knee. The cells in question must be capable of reaching the site of injury, adhering, and proliferating all while retaining a chondrogenic (or in the case of meniscus, fibrochondrogenic) cell phenotype. In many cases, the cells must be capable of filling and bridging large gaps by producing collagen matrices. The resulting repair tissue must be strong enough to remain intact as the joint is loaded and shear forces are applied to it.
Biomaterials for Meniscus Tissue Engineering
Biomaterials for meniscus tissue engineering can be synthesized from natural or synthetic components as raw materials. [45, [84] [85] [86] [87] [88] These biomaterials aim to provide 3D support and scaffolding, in addition to providing biomechanical support for this load-bearing tissue. Cell-free biomaterials have certain advantages such as ease-of-use, increased shelf life, availability, and cost. Non-biodegradable biomaterials can provide extended mechanical support, which is the most important function of meniscus. Forms of the commonly used biomaterials vary. Gel/ fluid-like components could be injectable and thus could be preferred for smaller defects. [85, 89, 90] Solid, stiff structures can provide 3D support and mechanical scaffolding to enhance the meniscal mechanical function, thereby supporting either preseeded cells or potential cell infiltration within the joint. [88] The biomaterial development for meniscus tissue engineering has been developing in parallel with tissue engineering efforts using cells and biomaterials together. Cell-laden biomaterials have the advantage of living cells replenishing any extracellular matrix that has been lost, and filling in as the biomaterials degrade over time. [91] 
Acellular Biomaterials
Cell-free biomaterials often provide 3D support and could be bioactive or bioinert. There are several clinically available scaffolds that are offered for partial meniscus repair.
Collagen Scaffolds
Currently in the United States, there is only one FDA-approved cell-free scaffold. Collagen meniscus implant (CMI) is derived from bovine type I collagen and molded in the shape of meniscus that offers restoration of tissue function. This scaffold is porous and upon implantation, cell infiltration has been reported in clinical studies. [92] However, long-term follow-up studies have demonstrated significant shrinkage of the implant, possibly due to degradation, which would lead to decreased biomechanical function. [93] Due to these limitations, CMI is unable to support the meniscus by itself when total meniscus replacement is necessary. CMI is available off the shelf as a crescentshaped device, which requires trimming by the surgeon to fit the partial meniscal defect. This could create potential size mismatch and thus change the mechanical environment in the knee joint potentially causing damage on the adjacent articular cartilage.
Polyurethane Scaffolds
Nondegradable synthetic solid polyurethane scaffolds were originally designed as total meniscus replacements, however a twoyear follow-up study using dogs indicated that the poly urethane implant was not chondroprotective, [84] possibly due to the lack of scaffold degradation at 24 months. [94] Vrancken et al. tested a synthetic solid, nondegradable, anatomically shaped polycarbonate urethane scaffold and compared it to the use of MAT in a biomechanical human cadaver model [95] and then a goat animal model. [96] Twelve-month follow-up after total meniscal replacement indicated that while the implant could not prevent the cartilage degeneration, the progression of damage was similar to MAT, in keeping with the results from the ex vivo human cadaver study. This example emphasizes the role of the validation of the biomechanical function in a biomechanical human cadaver model in the translation potential.
Polyurethane/Polycaprolactone Scaffolds
Actifit is an improved version of the polyurethane scaffolds that is recently developed as a biodegradable composite scaffold consisting of synthetic polymers poly-ɛ-caprolactone (PCL) (80%) and polyurethane (20%), approved for use in Europe, with clinical results similar to CMI. [97] Baynat et al. used Actifit for partial meniscus replacement in 18 patients in France. [98] Their two-year follow-up demonstrated cell infiltration into the porous polymer by chondrocytes and fibrochondrocytes and no adverse results were reported. However, only 50% of these young and active patients were able to return to their previous activity levels. [98] Leroy et al. reported a high failure rate and shrinkage in a fiveyear follow-up study using the Actifit poly urethane meniscal scaffold. [99] According to a recent systematic review, both Actifit and CMI meniscal scaffolds had lower reoperation and failure rates than MAT. [22] Both Actifit and CMI are somewhat effective in short-term restoration of function; however, shrinkage and irregularity in shape and dimension were observed in both. [97, 100] While these two biomaterials are promising, the clinically available cell-free implants are still not proven to function better than partial meniscectomy through randomized trials. [94] Recently, Elsner and co-workers have developed a cell-free anisotropic synthetic biomaterial (NUSurface), which started phase I clinical trials as an alternative to meniscal allograft transplantation for total meniscus replacements. This polycarbonate urethane (PCU) implant, reinforced with polyethylene, was first tested on sheep using an anatomically shaped version with fixation bolts on both horns. [7] Currently, the human clinical trials are conducted using a disc-shaped freefloating version of the implant, which is different from the version that was tested in sheep. [101] The method of fixation is instrumental for the fate of the implant as it can change the biomechanical environment in the joint.
Silk Scaffolds
Silk scaffolds are natural biomaterials that were proposed for the partial meniscal regeneration. [102, 103] When silk scaffolds were cultivated in vitro with human bone marrow stem cells, they exhibited improved mechanical properties, compared to acellular silk scaffolds. [104] The Fibrofix Meniscus scaffold, derived from silk is currently undergoing clinical trials. It was first tested in sheep for partial meniscus replacement model. Follow-up after three and six months demonstrated chondroprotective effects of the silk scaffold. [103] 4.1.5. Polycaprolactone Scaffolds 3D printing is an attractive method to fabricate biomaterials for meniscus repair because it could be customized for each patient to combat size-matching problems. In a recent study, a promising 3D printed fibrous PCL scaffold was combined with growth factor release, which includes growth factor-encapsulating polymer microspheres to direct cell differentiation or to induce cellular homeostasis. [88] This study employed MSCs seeded on this PCL scaffold for in vitro studies to demonstrate their differentiation into fibrochondrocytes, while the scaffold was used cellfree in the large animal study. The partial meniscus replacement in sheep using the 3D-printed PCL scaffolds demonstrated zonespecific type I and II collagen deposition. [88] This study emphasized the importance of in situ growth factor delivery systems in the development of biomaterials for meniscal tissue engineering, in an attempt to recreate the zonal variation in meniscus.
Fibrous scaffolds including PCL polymers have been electrospun to make cell-free biodegradable biomaterials for meniscus tissue engineering and have promising results. [105] Their main advantage is that they can provide the mechanical function early on, and they can degrade slowly, allowing time for the regeneration of meniscus matrix.
Polyvinyl Alcohol Scaffolds
Kobayashi et al. have proposed a non-biodegradable polyvinyl alcohol (PVA) hydrogel for the replacement of cartilage and meniscus, matching the mechanical properties with promising two-year follow-up results using rabbits. [106] However, a 12-month large animal study using sheep demonstrated that the cell-free non-biodegradable PVA hydrogel caused more cartilage degeneration on the tibial plateau than the meniscal allograft transplantation. [107] These studies demonstrate the importance of using clinically relevant large animal models for testing alternatives for meniscal allograft transplantation.
Decellularized Allograft Scaffolds
An alternative approach for creating a biomimetic cell-free bioscaffold for meniscus repair is the decellularization of the intact meniscus tissue. Decellularization of native tissue has the advantages of preserving the unique zonal organization of its ultrastructure and the instructive extracellular matrix components. These scaffolds would present the closest match to the MAT allografts. [108] Despite these significant advantages and the low immunogenic reaction potential, one major challenge has been to facilitate cell infiltration into these scaffolds due to the dense extracellular matrix structure, which may be alleviated by manually injecting cells into the graft, [109] introducing channels, [110] or using these scaffolds coupled with chemotactic agents. Decellularized scaffolds have been proposed as either xenografts with low immunogenic risks or they could be an alternative to the cryopreserved allografts. [109] Currently, there is no consensus in the optimum storage protocols for meniscal allografts. This variation in allograft storage protocols from different tissue banks leads to variation in cell viability in meniscus allografts, which could possibly affect the clinical outcomes. Frozen allografts often have dead cell debris which may have adverse effects. [111] The decellularization process allows for cleanup of cellular debris, which may be beneficial for the regeneration of new tissues.
In summary, acellular biomaterials have been developed from synthetic and natural materials, with demonstrated success in partial meniscus replacement. The major function of these biomaterials has been to provide 3D biomechanical support. Nondegradable materials have caused friction in the adjacent cartilage surfaces, therefore degradable biomaterials may have more potential for meniscus repair. [87] However, degradable biomaterials need a regenerative strategy to prevent shrinkage. Most promising approaches possibly use cellladen biomaterials (described in the following section) or use these biomaterials as a way to attract host cell infiltration, to ensure regeneration of meniscal extracellular matrix. Areas of improvement are the development of biomaterials that can be used for total meniscus replacement.
Cellular Biomaterials
Cell-laden biomaterials for meniscus tissue engineering vary in terms of their 3D structure. Injectable biomaterials are often used with cells because of the ease with which cells can be embedded in hydrogels. While they do not have the advantage of a robust 3D structure, their ease of use make injectables an attractive potential therapy for smaller meniscal defects. Decellularized extracellular matrix powders are often used to strengthen the biological activity of these hydrogels. Human bone marrow MSCs were embedded in hydrogels containing powderized bovine decellularized meniscus ECM and type I bovine collagen. [50] Injection of this MSC-laden meniscal ECMhydrogel in the articular joint space in an athymic nude rat model after meniscal injury was suggested to prevent hypertrophy when compared with MSC-laden type I collagen hydrogels. [50] Powderizing decellularized meniscal ECM has provided a biochemically inductive environment for the cells to differentiate or maintain their phenotype. Another major advantage is that because the intact ECM is dense and cell infiltration is limited, the digested ECM components can be homogeneously seeded with cells prior to injection. In addition, destroying the dense ECM structure enhances the host cell infiltration into the gels. [89] However, these biomaterials lack the ultrastructure and zonal organization of the collagen fibers in meniscus.
Some of the aforementioned acellular meniscus scaffolds have also been tested with cell seeding prior to implantation. Short-term studies in sheep demonstrated that autologous fibrochondrocyte cell-seeded CMI demonstrated improved healing and size retention. [75] 3D printed PCL scaffolds were seeded with allogeneic bone marrow derived stem cells and cultured for 24 hours prior to total meniscus replacement in a rabbit model. [112] Another rabbit study employed allogeneic fibrochondrocytes preseeded on PLDLA/PCL-T (poly(l-co-d,llactic acid)/poly(caprolactone-triol)) polymer scaffolds, cultured for 21 days prior to implantation. [77] Both studies showed that cell seeding seemed to improve the tissue-engineered meniscus properties after 12 and 24 weeks; however, these implants were not compared to MAT. In addition, the different biomechanics of the rabbit knee warrants more studies in large animal models that are necessary for clinical translation.
Most meniscus tissue engineering efforts use a homogeneous biomaterial approach to match the biochemical and mechanical properties of meniscus. One of the rarer approaches uses self-assembled allogeneic cells derived from the respective zones of meniscus to create a zonally differentiated tissue-engineered construct. [113] A similar approach uses cocultures with different cell combinations (articular chondrocytes, MSC, meniscal fibrochondrocytes either 100% in each zone or in cocultures, or cocultures of chondrocytes and either meniscus tendon or ligament cells) in the different regions of meniscus. [113, 114] The use of self-assembled cocultures of zone-specific cells can create a zonally organized matrix; however, possible drawbacks include the need for extremely high amount of cells and subsequent use of matrix-degrading enzymes to circumvent nutrient diffusion limitations, which could make the preclinical and clinical translation harder. A recent study demonstrated that the decellularized ECM fragments obtained from the inner and outer regions of meniscus could induce fibrocartilaginous and fibroblastic phenotype in hBMSCs, respectively. [115] These two approaches demonstrate that both different cell types and different matrix materials could be used for inducing the zonal variation in tissue-engineered meniscus.
Mechanical loading is another in vitro approach for the cultivation of functional tissue-engineered menisci with zonal variation. The meniscus is subject to strain levels ranging between 5 and 15% under physiologically relevant loading conditions. [116] The most commonly employed loading regimens include the application of dynamic compression at 10, 17, 18, or 15% strain [115] which have been shown to induce zonal differentiation in ECM production in tissue engineered meniscal constructs. [118] Here, we reported research studies employing cell-based tissue engineering methods, mainly using allogeneic cells, which may alleviate availability and morbidity problems associated with autologous cell sources. The main concern with the use of allogeneic cell is the risk of immune response by the host. Chondrocytes have been reported to generate little or no immune response in animal studies. [119] Similarly, meniscal allografts containing viable cells have been successfully implanted with no adverse immune reaction. [120] In vitro cocultures of articular chondrocytes or meniscus cells with peripheral blood mononuclear cells showed no proliferative response in the blood cells, which would be expected in the event of immune rejection. [121] Taken together, these studies imply that meniscus and cartilage cells share immuno-privileges, which means they could be used as allogeneic cell sources that cause little or no immune response when implanted.
Regardless of cellularity, functional implants for meniscal repair require validation using large animal models. While one year is typically recommended to observe whether implants cause joint degeneration, incidences of joint degeneration have been reported in cell-free meniscus implantation as early as after four months in animal models. [81] Functional improvement can be detected at six months as reported by different research groups. [7, 103, 122] While cartilage degeneration after meniscal injury in large animal models takes months to be detectable by histology, others have observed cartilage degeneration as soon as 28 days after meniscal resection, when daily 20 minute exercise (walking and climbing one step) was incorporated after surgery in minipigs. [123] It is important to consider meniscal allograft transplantation as a control group in these animal studies to assess if the proposed tissue engineered solution can provide a functional replacement, and an alternative to the current standard of care. Ex vivo testing of the mechanical outcome of an implant is another way to ensure success in preclinical studies. Vrancken et al. [95] used human cadaveric knees to assess the effects of implants in comparison to total meniscectomy and allograft transplantation on knee kinematics. This type of assessment may provide guidance prior to in vivo animal experiments.
Conclusion
Meniscal repair or replacement should be decided on a caseby-case basis. In situations where isolated cuts/tears or small defect occur, the use of cell-based repair methods is more suitable over total meniscus replacement since significant tissue loss is not a factor that needs to be addressed. However, in situations where entire portions of tissue need to be surgically removed or reshaped, meniscus replacement is a justifiable and necessary therapeutic strategy.
In the past decade, strategies that implement different cell types and newly developed novel biomaterials for meniscus repair and replacement have been designed and tested in animals. Now that partial meniscus replacements are available, research efforts have focused on developing functional total meniscus replacements. Matching the mechanical properties is a priority for tissues like meniscus and cartilage. Nondegradable polymers have been proposed as a mechanical replacement, however they present long-term problems such as adjacent cartilage damage, or integration issues due to lack of cell infiltration. Other important design considerations in tissue engineered meniscus replacements include tribological properties and mimicking the cell alignment in the direction of collagen. [124] In cases where meniscal replacement is necessary, we envision a "living" replacement that is an amalgamation of biomimetic scaffold and cells to have a longer and sustainable in vivo life. The size variation in human menisci [125] is an important parameter in designing functional implants. 3D printing techniques offer size matching using imaging such as MR. Our vision includes cells that could possibly include allogeneic sources, with anatomically shaped size-matched bioactive biomaterials (Figure 4) . Growth factor delivery systems ensure the meniscal cellular phenotype to be preserved. An alternative approach is to use gene therapy to stimulate growth factor synthesis pathways for meniscal repair. [126] Using supportive biomaterials with a slow degradation rate could ensure mechanical function and provide a viable option using less cells than a cell-only approach. These biocomposites need to be assessed for biomechanical properties before the preclinical animal implantation studies.
In this progress report, we discussed different approaches for meniscus tissue engineering and regeneration. The major hurdles in engineering a meniscus include the inability to mimic the native meniscus structure, and hence functiondue to differences in cellular phenotypes, ECM composition, and mechanical properties spanning the zonal variations in the inner and outer regions of normal menisci. The design efforts have traditionally overlooked the zonal differentiation of the meniscus replacements. For cell-based meniscus tissue engineering, zonal approaches using different biomaterials in combination with different cell types, perhaps specialized cells (from these specific regions) or different cues (biochemical or material or mechanical cues) to differentiate into zonal phenotypes in meniscus. We envision that the design of zone-specific engineered tissues will lead to functional clinical therapies.
